UB17:LSE:LSE-UBS MSCI EMU Value UCITS EUR Adis (GBX)

ETF | Others |

Last Closing

USD 3782.75

Change

-53.50 (-1.39)%

Market Cap

N/A

Volume

189.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-4.75 (-2.49%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-0.84 (-0.70%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.08 (-0.45%)

USD 572.76B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.05 (-0.38%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.25 (-0.35%)

USD 266.08B
0QZO:LSE 0QZO

-1.05 (-1.09%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

-4.82 (-2.77%)

USD 202.26B
PRJU:LSE Amundi Index Solutions - Amund..

-0.12 (-0.38%)

USD 200.79B
0R24:LSE Intel Corp.

-0.35 (-1.47%)

USD 196.14B

ETFs Containing UB17:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.03% 37% F 45% F
Dividend Return 0.04% 33% F 45% F
Total Return 4.07% 35% F 44% F
Trailing 12 Months  
Capital Gain 11.87% 43% F 49% F
Dividend Return 0.04% 31% F 39% F
Total Return 11.91% 40% F 48% F
Trailing 5 Years  
Capital Gain 20.45% 42% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.45% 39% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 6.86% N/A N/A 62% D
Dividend Return 6.86% N/A N/A 61% D-
Total Return 0.00% N/A N/A 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 13.27% N/A N/A 69% C-
Risk Adjusted Return 51.71% N/A N/A 75% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike